Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Pulmonx Corporation

Market Cap 54.06M 47.11M 43.42M 40.84M 76.41M 5.1B 76.95M 517M 201M 2.51B 203M 199M 8.7B P/E 2026 *
-1.12x
P/E 2027 * -1.23x
Enterprise Value 54.06M 47.11M 43.42M 40.84M 76.41M 5.1B 76.95M 517M 201M 2.51B 203M 199M 8.7B EV / Sales 2026 *
0.6x
EV / Sales 2027 * 0.55x
Free-Float
95.11%
Yield 2026 *
-
Yield 2027 * -
1 day+2.40%
1 week-9.86%
Current month-22.42%
1 month-2.29%
3 months-13.51%
6 months-49.21%
Current year-42.08%
1 week 1.22
Extreme 1.22
1.39
1 month 1.22
Extreme 1.22
1.72
Current year 1.13
Extreme 1.13
2.39
1 year 1.13
Extreme 1.13
3.88
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.81
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 2025-10-26
Director of Finance/CFO 53 2019-04-30
Chief Tech/Sci/R&D Officer - 2020-01-31
Director TitleAgeSince
Director/Board Member 72 2007-01-31
Director/Board Member 64 2014-12-17
Chairman 66 2019-09-30
Date Insider Type Main position Quantity % Market Cap.
06-04Free

Director

40,000 0.0947%
06-04Free

Director

40,000 0.0947%
06-04Free

Director

40,000 0.0947%
Change 5-day change 1-year change 3-year change Capi.($)
+2.40%-9.86%-53.45%-89.86% 54.06M
-0.01%+0.01%+0.01%+13.73% 12.57B
+0.33%-0.35%+23.42%-5.98% 12.48B
+0.01%0.00%+10.55%+11.44% 9.42B
-1.61%-3.93%+54.58%+24.80% 5.85B
+0.23%+2.84%+5.32%-23.24% 5.53B
+0.05%-.--%-.--%+37.08% 4.7B
-2.42%-4.02%-30.82%+13.50% 4B
+4.23%-4.52% - - 4.15B
-2.06%-2.37%-30.05%-26.67% 3.65B
Average +0.12%-2.96%-2.27%-5.02% 6.24B
Weighted average by Cap. -0.05%-1.39%+8.66%+5.98%

Financials

2026 *2027 *
Net sales 90.77M 79.09M 72.91M 68.58M 128M 8.55B 129M 867M 337M 4.22B 341M 333M 14.61B 98.07M 85.45M 78.77M 74.09M 139M 9.24B 140M 937M 364M 4.55B 368M 360M 15.79B
Net income -47.97M -41.8M -38.53M -36.24M -67.8M -4.52B -68.28M -458M -178M -2.23B -180M -176M -7.72B -44.58M -38.84M -35.8M -33.68M -63M -4.2B -63.44M -426M -165M -2.07B -167M -164M -7.18B
Net Debt - -
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
26-06-18 1.280 $ +2.40% 619,926
26-06-17 1.250 $ 0.00% 293,294
26-06-16 1.250 $ -2.34% 610,633
26-06-15 1.280 $ -6.57% 751,315
26-06-12 1.370 $ -3.52% 226,225
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.280USD
Average target price
3.400USD
Spread / Average Target
+165.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUNG Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!